{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:34:55Z","timestamp":1791660895406,"version":"4.3.4"},"reference-count":40,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Antibiotic resistance undermines conventional\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>Helicobacter pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      (\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H.\u2009pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      ) eradication therapies. Tegoprazan\u2013amoxicillin (TA) dual therapy is a promising alternative, but its efficacy and safety compared with other treatment regimens remain unclear. The aim of this meta\u2010analysis was to comprehensively evaluate the efficacy and safety of TA dual therapy in eradicating\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H.\u2009pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PubMed, Embase, CENTRAL, and Web of Science were searched from inception to December 2025. Eligible randomized controlled trials (RCTs) compared TA dual therapy with bismuth\u2010containing quadruple therapy (BQT) or proton pump inhibitor (PPI)\u2013based high\u2010dose dual therapy (PPI\u2010HDDT) in adults with\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H.\u2009pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      infection. The outcomes were\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H.\u2009pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      eradication rate, adverse events, and medication adherence. Evidence quality was assessed via GRADE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six RCTs (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091909) were included. TA dual therapy showed no significant difference in eradication rate compared with BQT (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095 RCTs, ITT analysis: 78.0% vs. 81.4%, RR\u2009=\u20090.97, 95% CI: 0.88\u20131.05,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.44; PP analysis: 84.6% vs. 86.2%, RR\u2009=\u20090.96, 95% CI: 0.87\u20131.06,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.39; low\u2010quality evidence), confirmed by trial sequential analysis. TA dual therapy had a lower overall adverse event rate (11.3% vs. 22.5%, RR\u2009=\u20090.50, 95% CI: 0.37\u20130.67,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001; moderate\u2010quality evidence) but similar adherence (95.7% vs. 94.5%, RR\u2009=\u20091.01, 95% CI: 0.99\u20131.03,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.31; moderate\u2010quality evidence) compared with BQT. Efficacy and safety were comparable between TA dual therapy and PPI\u2010HDDT (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091 RCT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The TA dual therapy exhibits similar efficacy compared with BQT and PPI\u2010HDDT for\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>H.\u2009pylori<\/jats:italic>\n                      <\/jats:styled-content>\n                      eradication, with a better safety profile compared with BQT. However, its overall eradication efficacy is suboptimal, necessitating further regimen optimization in the future.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jgh.70498","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:41:51Z","timestamp":1781793711000},"page":"2265-2277","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of Tegoprazan\u2013Amoxicillin Dual Therapy for\n                    <scp>\n                      <i>Helicobacter pylori<\/i>\n                    <\/scp>\n                    Eradication: A Systematic Review and Meta\u2010Analysis With Trial Sequential Analysis of Randomized Controlled Trials"],"prefix":"10.1111","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6096-3034","authenticated-orcid":false,"given":"Ben\u2010Gang","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Gastroenterology Northern Jiangsu People's Hospital, Yangzhou University  Yangzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye\u2010Min","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Northern Jiangsu People's Hospital, Yangzhou University  Yangzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010Jun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Northern Jiangsu People's Hospital  Yangzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Northern Jiangsu People's Hospital, Yangzhou University  Yangzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Northern Jiangsu People's Hospital, Yangzhou University  Yangzhou Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.12.022"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01171-1"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.12.033"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002968"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002546"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.04.006"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000132"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00003-3"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002565"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl15502"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0012-x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16295"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-025-03850-6"},{"issue":"1","key":"e_1_2_11_16_1","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13040","article-title":"Vonoprazan\u2010Amoxicillin Dual Therapy Versus Bismuth\u2010Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta\u2010Analysis","volume":"29","author":"Zhou B. G.","year":"2024","journal-title":"Helicobacter: The Official Journal of the International Society for Helicobacter and Related Bacteria"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00377-8"},{"key":"e_1_2_11_22_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (Updated August 2024)","author":"Higgins J. P. T.","year":"2024"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/ija.ija_1051_24"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0315-7"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13098"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13151"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000699"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1629567"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.70180"},{"key":"e_1_2_11_30_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562848251391276","article-title":"Comparison of Tegoprazan\u2010Based High\u2010Dose Dual Therapy Versus Bismuth\u2010Containing Quadruple Therapy for Helicobacter pylori Eradication: A Prospective, Multicentre, Randomised Controlled Trial in Gansu Province, a High\u2010Resistance Region of China","volume":"18","author":"Yang J.","year":"2025","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.192757"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1805"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2544886"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15268"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2010.08.007"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00281-9"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70070"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl20247"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1580203"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2025.2459722"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.70004"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.70498","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jgh.70498","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.70498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:59:42Z","timestamp":1785769182000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.70498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/jgh.70498"],"URL":"https:\/\/doi.org\/10.1111\/jgh.70498","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"2026-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}